Last updated: March 2026
Epitalon (AEDG) is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of epithalamin — a natural pineal gland extract. Studied across 775+ publications, it activates telomerase to extend cellular lifespan and produced 44% telomere extension in human cell line studies.
Epitalon (also written Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of epithalamin — a natural pineal peptide extract used in Russian longevity research since the 1970s.
Epitalon binds to the ATTTC sequence in the telomerase gene promoter, inducing hTERT expression and telomerase activity. This leads to telomere elongation in somatic cells — observed in human fetal fibroblasts (Khavinson, Bull Exp Biol Med 2003, PMID: 12937682).
Restores melatonin and cortisol circadian rhythms in aging primates. In old rhesus monkeys, Epitalon normalized the 24-hour secretion pattern of melatonin — a key aging marker — suggesting pineal gland restoration rather than direct melatonin replacement.
Epigenetic regulation via histone interaction — specifically H1/3 and H1/6 subtypes. Like other Khavinson bioregulators, Epitalon enters the cell nucleus and interacts directly with DNA-protein complexes, modulating gene expression without receptor binding.
The pineal gland and retina share embryonic origin (both derived from neuroectoderm). Epitalon prolongs retinal cell integrity in aging animal models. Observed protection against age-related photoreceptor degeneration in multiple studies.
Data from Khavinson's program and independent replications. Most studies are animal or cell models — context is provided for each finding.
Research context matters: The bars below span cell studies, animal models, and limited human data. Results from cell lines and mice do not guarantee identical effects in humans. Russian clinical data is extensive but often lacks the RCT design required for Western regulatory approval.
Khavinson's research is extensive — but important caveats apply before drawing clinical conclusions.
Doses used in Khavinson's research program and current community practice. These are research-context doses — not medical prescriptions.
Cycling Protocol: 10–30 days on → 2–3 months off → repeat 1–3 times per year. This matches the pattern used in Khavinson's long-term animal studies and the Russian clinical program. Continuous use has not been studied long-term. FDA Status: NOT approved for human use. Research compound only. Research Use Only
Primary research behind the data on this page. Click PMID links to read full papers on PubMed.
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
⚕️ Always consult a healthcare provider before starting any peptide protocol.
An honest assessment of where Epitalon research stands as of 2026.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Essential supplies for peptide research. These are general research supplies — not Epitalon itself.
Affiliate links help support MeetPeptide at no extra cost to you.
This page is for educational and informational purposes only. It is not medical advice, and nothing here should be interpreted as a recommendation to use Epitalon or any peptide. Epitalon (AEDG) is NOT approved by the FDA for human use. It is a research compound available only for laboratory and investigational purposes. The majority of studies cited are preclinical (cell culture and animal models). Russian clinical data, while extensive, has not been evaluated by Western regulatory agencies under current RCT standards. Always consult a qualified healthcare provider before making any decisions about your health. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.